CAR-T cell therapy in developing countries: how long should we wait?
Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatment...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-12-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/12/e009611.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832584904347484160 |
|---|---|
| author | Om P Kurmi Ramila Shilpakar Sanjivan Gautam Balram Gautam Sudhamshu K C |
| author_facet | Om P Kurmi Ramila Shilpakar Sanjivan Gautam Balram Gautam Sudhamshu K C |
| author_sort | Om P Kurmi |
| collection | DOAJ |
| description | Low- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.The Center for Regenerative Medicine in Nepal has initiated efforts to make CAR-T cell therapy accessible to patients with cancer at a substantially reduced cost. This initiative includes successful research to test the feasibility of local laboratory capabilities using reagents sourced locally or from developed countries. Additionally, a Good Manufacturing Practicies (GMP) grade CAR-T cell manufacturing facility is being established to commence clinical manufacturing. This endeavor has encountered several challenges, including technical difficulties, regulatory barriers, and resource limitations, which could provide valuable insights for other developing countries. This experience from Nepal highlights the importance of interdisciplinary collaboration, shared knowledge, funding, and innovative solutions from the global scientific community to achieve equitable access to advanced medical treatments. |
| format | Article |
| id | doaj-art-019346a9bf924d32952da01e571338ab |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-019346a9bf924d32952da01e571338ab2025-01-27T08:00:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-12-01121210.1136/jitc-2024-009611CAR-T cell therapy in developing countries: how long should we wait?Om P Kurmi0Ramila Shilpakar1Sanjivan Gautam2Balram Gautam3Sudhamshu K C4Center for Regenerative Medicine, Kathmandu, NepalCenter for Regenerative Medicine, Kathmandu, NepalCenter for Cancer Research, National Cancer Institute, Bethesda, Maryland, USACenter for Regenerative Medicine, Kathmandu, NepalCenter for Regenerative Medicine, Kathmandu, NepalLow- and middle-income countries (LMICs) face a significant burden of cancer prevalence and incidence. However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.The Center for Regenerative Medicine in Nepal has initiated efforts to make CAR-T cell therapy accessible to patients with cancer at a substantially reduced cost. This initiative includes successful research to test the feasibility of local laboratory capabilities using reagents sourced locally or from developed countries. Additionally, a Good Manufacturing Practicies (GMP) grade CAR-T cell manufacturing facility is being established to commence clinical manufacturing. This endeavor has encountered several challenges, including technical difficulties, regulatory barriers, and resource limitations, which could provide valuable insights for other developing countries. This experience from Nepal highlights the importance of interdisciplinary collaboration, shared knowledge, funding, and innovative solutions from the global scientific community to achieve equitable access to advanced medical treatments.https://jitc.bmj.com/content/12/12/e009611.full |
| spellingShingle | Om P Kurmi Ramila Shilpakar Sanjivan Gautam Balram Gautam Sudhamshu K C CAR-T cell therapy in developing countries: how long should we wait? Journal for ImmunoTherapy of Cancer |
| title | CAR-T cell therapy in developing countries: how long should we wait? |
| title_full | CAR-T cell therapy in developing countries: how long should we wait? |
| title_fullStr | CAR-T cell therapy in developing countries: how long should we wait? |
| title_full_unstemmed | CAR-T cell therapy in developing countries: how long should we wait? |
| title_short | CAR-T cell therapy in developing countries: how long should we wait? |
| title_sort | car t cell therapy in developing countries how long should we wait |
| url | https://jitc.bmj.com/content/12/12/e009611.full |
| work_keys_str_mv | AT ompkurmi cartcelltherapyindevelopingcountrieshowlongshouldwewait AT ramilashilpakar cartcelltherapyindevelopingcountrieshowlongshouldwewait AT sanjivangautam cartcelltherapyindevelopingcountrieshowlongshouldwewait AT balramgautam cartcelltherapyindevelopingcountrieshowlongshouldwewait AT sudhamshukc cartcelltherapyindevelopingcountrieshowlongshouldwewait |